Carbon Cybernetics presents presented audiences at The University of Melbourne, unveiling our revolutionary device set to transform the landscape of neurological treatment. This pioneering technology promises to usher in a new era for individuals battling epilepsy and other complex neurological
5 December 2023 Neural implant technology developer Carbon Cybernetics is pleased to announce it has received a pre-seed investment from the University of Melbourne, as it also welcomes the appointment of new CEO Justin Spangaro. Carbon Cybernetics emerged from the
CEO David Garret shares Carbon Cybernetics’ journey to discovering a functional cure for epilepsy. Known for his work developing novel materials for use inside the body, David reveals the latest project the Carbon Cybernetics team have developed to detect the
Congratulations David! With ten years of innovation in medical device technology, – particularly in novel materials for neural interface applications – A/Prof (and CEO) David Garrett is an internationally regarded research scientist invested in developing high-performance electrodes for use inside
Our journey so far… Our work in miniaturised neural implants is making big strides and now, we’re up for a prestigious prize at this year’s upcoming Eureka Awards for excellence in interdisciplinary scientific research! We sat down with Patton’d Studios’
Our latest media feature Carbon Cybernetics has been featured as one of the University of Melbourne’s research case studies. In the latest media release, they describe the latest research the team here at Carbon Cybernetics have been working on –
BioMedTech Horizons grant to develop a miniaturised neural implant The Australian Government is investing $18.8 million to boost efforts towards finding better treatments for cancer, epilepsy, stroke, paralysis, Irritable Bowel Syndrome (IBS), brain injuries, back pain and other chronic diseases.
New publication in Nature Communications We are very pleased to announce that our latest research entitled “Critical slowing down as a biomarker for seizure susceptibility” has been published in the May issue of Nature communications. The research explores the way